
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia
Treatment with revumenib produced clinically meaningful responses in an older population of patients with heavily pretreated relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations, according to findings from the phase 2 portion of …